Shares of Chimerix Inc. (NASDAQ:CMRX) traded down 1.2% during mid-day trading on Friday . The stock traded as low as $3.92 and last traded at $3.98, with a volume of 219,712 shares trading hands. The stock had previously closed at $4.03.

Several analysts recently issued reports on the company. FBR & Co reissued a “hold” rating on shares of Chimerix in a research note on Tuesday, May 10th. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Wednesday, May 11th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $16.98.

The stock has a 50 day moving average price of $4.25 and a 200-day moving average price of $6.37. The stock’s market cap is $184.39 million.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.09. The firm earned $1.20 million during the quarter, compared to analyst estimates of $2.79 million. On average, analysts expect that Chimerix Inc. will post ($2.06) earnings per share for the current year.

In related news, CEO M Michelle Berrey bought 13,188 shares of the stock in a transaction dated Friday, June 24th. The shares were purchased at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the completion of the purchase, the chief executive officer now directly owns 258,821 shares of the company’s stock, valued at $955,049.49. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ernest Mario bought 25,000 shares of the stock in a transaction dated Wednesday, May 11th. The stock was bought at an average price of $4.85 per share, for a total transaction of $121,250.00. Following the purchase, the director now directly owns 297,240 shares of the company’s stock, valued at $1,441,614. The disclosure for this purchase can be found here.

Other hedge funds recently modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock worth $11,400,000 after buying an additional 515,029 shares during the last quarter. Trexquant Investment LP increased its stake in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 107,484 shares during the last quarter. Morgan Stanley increased its stake in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock worth $1,674,000 after buying an additional 92,005 shares during the last quarter. Finally, Numeric Investors LLC bought a new stake in shares of Chimerix during the fourth quarter worth approximately $2,076,000.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.